Evidence map›Paper›PMID 32436077›Full record

ArticleActa neurologica Belgica2021

Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.

C Quarracino, M Bendersky, R Rey, G E Rodríguez

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C QuarracinoNeurology Department, Instituto de Investigaciones Médicas Alfredo Lanari, Av. Combatientes de Malvinas 3150, Buenos Aires, Argentina. cecquarr@hotmail.com.ORCID http://orcid.org/0000-0002-9162-9626
M BenderskyIII Normal Anatomy Department (Living Anatomy Laboratory), School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
R ReyNeurology Department, Instituto Argentino de Investigación Neurológica (IADIN), Uruguay 824, Buenos Aires, Argentina.
G E RodríguezNeurology Department, ALS Clinic, Hospital Ramos Mejía, Gral. Urquiza 609, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 2015, edaravone is the second drug available for the treatment of Amyotrophic lateral sclerosis (ALS). In this study we analyzed the characteristics and experience of ALS patients treated with this new medication in our country. Sixteen ALS patients were treated with edaravone infusions in three ALS clinics. Most of them were male, had a spinal onset of the disease and a definite diagnosis of ALS. Mean age at first infusion was 53.5 years. Since the diagnosis of ALS, delay in starting treatment with edaravone was five times greater than that of riluzole. Edaravone therapy was usually initiated at a health care facility and was followed by domiciliary cycles. Adverse effects and the need of a special catheter for infusion were rare. Access to edaravone through health insurance was possible in only 43.8% of patients. Altogether, treatment access was limited but feasible and edaravone was well tolerated.

Indexed as

AdultAgedAmyotrophic Lateral SclerosisArgentinaDrug Administration RoutesEdaravoneFemaleHumansMaleMiddle AgedNeuroprotective AgentsEdaravoneNeuroprotective AgentsAdverse effectsAmyotrophic lateral sclerosisEdaravoneSafety

Identifiers

PMID32436077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.